TY - JOUR
T1 - Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
AU - Baselli, Guido Alessandro
AU - Dongiovanni, Paola
AU - Rametta, Raffaela
AU - Meroni, Marica
AU - Pelusi, Serena
AU - Maggioni, Marco
AU - Badiali, Sara
AU - Pingitore, Piero
AU - Maurotti, Samantha
AU - Montalcini, Tiziana
AU - Taliento, Alice Emma
AU - Prati, Daniele
AU - Rossi, Giorgio
AU - Fracanzani, Anna Ludovica
AU - Mancina, Rosellina Margherita
AU - Romeo, Stefano
AU - Valenti, Luca
PY - 2020
Y1 - 2020
N2 - Objective: Efforts to manage non-alcoholic fatty liver disease (NAFLD) are limited by the incomplete understanding of the pathogenic mechanisms and the absence of accurate non-invasive biomarkers. The aim of this study was to identify novel NAFLD therapeutic targets andbiomarkers by conducting liver transcriptomic analysis in patients stratified by the presence of the PNPLA3 I148M genetic risk variant. Design: We sequenced the hepatic transcriptome of 125 obese individuals. 'Severe NAFLD' was defined as the presence of steatohepatitis, NAFLD activity score ≥4 or fibrosis stage ≥2. The circulating levels of the most upregulated transcript, interleukin-32 (IL32), were measured by ELISA. Results: Carriage of the PNPLA3 I148M variant correlated with the two major components of hepatic transcriptome variability and broadly influenced gene expression. In patients with severe NAFLD, there was an upregulation of inflammatory and lipid metabolism pathways. IL32 was the most robustly upregulated gene in the severe NAFLD group (adjusted p=1×10-6), and its expression correlated with steatosis severity, both in I148M variant carriers and non-carriers. In 77 severely obese, and in a replication cohort of 160 individuals evaluated at the hepatology service, circulating IL32 levels were associated with both NAFLD and severe NAFLD independently of aminotransferases (p<0.01 for both). A linear combination of IL32-ALT-AST showed a better performance than ALT-AST alone in NAFLD diagnosis (area under the curve=0.92 vs 0.81, p=5×10-5). Conclusion: Hepatic IL32 is overexpressed in NAFLD, correlates with hepatic fat and liver damage, and is detectable in the circulation, where it is independently associated with the presence and severity of NAFLD.
AB - Objective: Efforts to manage non-alcoholic fatty liver disease (NAFLD) are limited by the incomplete understanding of the pathogenic mechanisms and the absence of accurate non-invasive biomarkers. The aim of this study was to identify novel NAFLD therapeutic targets andbiomarkers by conducting liver transcriptomic analysis in patients stratified by the presence of the PNPLA3 I148M genetic risk variant. Design: We sequenced the hepatic transcriptome of 125 obese individuals. 'Severe NAFLD' was defined as the presence of steatohepatitis, NAFLD activity score ≥4 or fibrosis stage ≥2. The circulating levels of the most upregulated transcript, interleukin-32 (IL32), were measured by ELISA. Results: Carriage of the PNPLA3 I148M variant correlated with the two major components of hepatic transcriptome variability and broadly influenced gene expression. In patients with severe NAFLD, there was an upregulation of inflammatory and lipid metabolism pathways. IL32 was the most robustly upregulated gene in the severe NAFLD group (adjusted p=1×10-6), and its expression correlated with steatosis severity, both in I148M variant carriers and non-carriers. In 77 severely obese, and in a replication cohort of 160 individuals evaluated at the hepatology service, circulating IL32 levels were associated with both NAFLD and severe NAFLD independently of aminotransferases (p<0.01 for both). A linear combination of IL32-ALT-AST showed a better performance than ALT-AST alone in NAFLD diagnosis (area under the curve=0.92 vs 0.81, p=5×10-5). Conclusion: Hepatic IL32 is overexpressed in NAFLD, correlates with hepatic fat and liver damage, and is detectable in the circulation, where it is independently associated with the presence and severity of NAFLD.
KW - cytokines
KW - genetics
KW - nonalcoholic steatohepatitis
KW - RNA expression
UR - http://www.scopus.com/inward/record.url?scp=85078957333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078957333&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2019-319226
DO - 10.1136/gutjnl-2019-319226
M3 - Article
C2 - 32001554
AN - SCOPUS:85078957333
VL - 69
SP - 1855
EP - 1866
JO - Gut
JF - Gut
SN - 0017-5749
IS - 10
ER -